Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

溫州康寧醫院股份有限公司

nt stock limite

GE E AL I F MA I CHE GD E I A D ICH A H GJI

Chengdu Renyi is a company established in the PRC with limited liability, and it is a for-profit general hospital, which primarily focuses on providing geriatric and psychiatric medical services and has 299 registered beds.

As advised by Chengdu Renyi, its existing sole shareholder, Sichuan Hongji, is a company established in the PRC with limited liability. The principal business of Sichuan Hongji includes sales and distribution of pharmaceutical products and medical facilities.

EA F HE E I I E ME

By entering into the Subscription Agreement, the Company will further enhance its medical network layout in Sichuan Province. The Directors are of the view that the Equity Investment is consistent with the long-term development goal and strategy of the Company, and is in the interests of the Company and its shareholders as a whole.

LI I G LE IM LICA I

As the applicable percentage ratios (as defined in Rule 14.07 of the Listing Rules) in respect of the Equity Investment do not exceed 5%, the Equity Investment does not constitute a notifiable transaction for the Company pursuant to Chapter 14 of the Listing Rules.

A C / w , w , A , E y I y y C . C y w C y.

E M ED I HI A CEME

In this announcement, unless the context otherwise requires, the following words and expressions shall have the meanings given to them as below:

"Board"	the board of Directors
"Chengdu Renyi"	Chengdu Renyi Hospital Company Limited* (成都仁一醫院有限公司), a limited liability company established in the PRC
"Company"	Weznhou Kangning Hospital Co., Ltd. (stock code: 2120)

"Completion"	the completion of the Equity Investment pursuant to the terms and conditions of the Subscription Agreement
"Consideration"	the total consideration payable by Zhejiang Kangning to Chengdu Renyi for the Equity Investment pursuant to the Subscription Agreement, being RMB15,000,000 (equivalent to approximately HK$18,033,181)
"Director(s)"	the director(s) of the Company

"Sichuan Hongji"	Sichuan Hongji Pharmaceutical Company Limited * (四川省宏 藥業有限責任公司), a limited liability company established in the PRC and the existing shareholder holding as to 100% equity interest in Chengdu Renyi
"Subscription Agreement"	the conditional agreement dated September 11, 2017, entered into among Sichuan Hongji, Chengdu Renyi and Zhejiang Kangning in relation to the Equity Investment
"Target Equity Interest"	41.67% equity interests in Chengdu Renyi upon the Completion
"Zhejiang Kangning"	Zhejiang Kangning Hospital Management Co., Ltd., a limited liability company established in the PRC and a wholly-owned subsidiary of the Company
"%"	per cent

* *The English translation in this announcement is for identification purpose only. The official names are in Chinese.*

By order of the Board
K H C ., L .
G A
Chairman

Zhejiang, the PRC
September 12, 2017

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. YANG Yang and Mr. LIN Lijun; and the independent non-executive directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and